NCT05511428View on ClinicalTrials.gov

Home Based Daratumumab Administration for Patients With Multiple Myeloma

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

November 8, 2022

Primary Completion Date

May 22, 2024

Study Completion Date

May 22, 2024

Conditions
Plasma Cell Myeloma
Interventions
DRUG

Daratumumab and Hyaluronidase-fihj

Given SC

OTHER

Questionnaire Administration

Ancillary studies

OTHER

Quality-of-Life Assessment

Ancillary studies

OTHER

Interview

Ancillary studies

Trial Locations (1)

19107

Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia

All Listed Sponsors
collaborator

Janssen Scientific Affairs, LLC

INDUSTRY

lead

Thomas Jefferson University

OTHER